Royalty Report: Drugs, Disease, Therapeutic – Collection: 279342

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 12

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Gastrointestinal
  • Pain
  • Pharmaceuticals
  • Diagnostic
  • Drug Discovery
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279342

License Grant
Licensor hereby grants to the Puerto Rico Licensee in the Field an exclusive (even as to Licensor, other than as set forth in this agreement (Retained Rights)) license under the Licensor Technology and Joint Technology, with the right to sublicense as set forth in this agreement (Sublicenses), to make, have made, use, Develop, sell, offer to sell, have sold, import, export, and otherwise exploit and Commercialize the Compound and Products in the Territory. Licensee acknowledges that with respect to those Licensor Patent Rights that are Controlled by Licensor pursuant to the Third Party Agreements, the foregoing license is subject to the rights of the Third Party licensors under such Third Party Agreements.
License Property
Product means a product containing the Compound as an active ingredient, including without limitation a Combination Product.

Combination Product means any Product that contains the Compound as an active ingredient together with one or more other active ingredients and is sold for a single invoiced price, e.g., where the Compound is packaged for sale together with a second compound or biologic as an active ingredient (either as a single fixed dose or as separate doses).

Compound means R-methyinaltrexoun (R-MNTX) which is chemically defined as morphinanium, 17R, 17-(cyclopropylmethyl)-4, 5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5a)-(9C1), and its pharmacologically acceptable salts, together with their solvates, hydrates, hemihydrates, metabolites, pro-drugs, esters, and if applicable, any isomers or racemates thereof, but excluding any of the foregoing olecules whose primary mechanism of action is as an opioid agonist. The “Compound” does not include the Excluded Molecules.

Licensor Patent Rights means any Patent Right Controlled by Licensor or its Affiliates as of the Effective Date or at any time during the Term that relates to, claims, or if issued, would be infringed by an unlicensed Third Party’s manufacture, use, sale, importation, Development or Commercialization of the Compound, or any Product; provided, however, that if a Third Party becomes an Affiliate of Licensor pursuant to a transaction or series of related transactions as a result of which such Third Party is able to elect a majority of the members of the board of directors of Licensor (or its successor company) or any of its “controlling Affiliates” (as defined in this agreement) (Licensor Change of Control), “Licensor Patent Rights” will not include any Patent Rights that were Controlled by such Third Party prior to the completion of such transaction or series of related transactions. Licensor Patent Rights are identified as:
4,719,215 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
4,861,781 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
5,102,887 – Method for reducing emesis and nausea induced by the administration of an emesis causing agent

Joint Patent Rights means any Patent Rights related to any invention, development or discovery made or created in the course of the Collaboration jointly by (i) employees or agents of Licensor or any of its Affiliates, and (ii) employees or agents of Licensee or any of its Affiliates, as determined in accordance with this agreement (Inventorship).

Licensor Technology means the Licensor Know-How and the Licensor Patent Rights.

Joint Technology means the Joint Know-How and the Joint Patent Rights.

To relieve pain, narcotic medications such as morphine activate specific opioid receptors located in the central nervous system – the brain and spinal cord. Opioids, however, also interact with these receptors outside of the central nervous system, resulting in side effects, which can be debilitating, including constipation, urinary retention and severe itching. MNTX is designed to block peripheral opioid receptors whose activation causes these side effects. As MNTX does not cross the blood-brain barrier, it does not interfere with brain-centered pain relief.

Field of Use
The agreement is for the joint development and commercialization of methylnaltrexone (MNTX) for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. These medical conditions are major therapeutic challenges in the management of gastrointestinal function in individuals treated with opioids for pain or in patients following serious or prolonged surgeries.

IPSCIO Record ID: 279343

License Grant
Licensee is hereby exercising its option to acquire an exclusive license to make, use, and sell N-methylnaltrexone and any of its congeners under U.S. Patent 4,176,186.  In all other respects the agreement of May 8, 1985 shall remain in effect as previously agreed.
License Property
Patents shall mean U.S. Patent 4,176,186 as well as any patent application filed respecting other uses of the Compound, and corresponding foreign patents.

4,176,186 – Quaternary derivatives of noroxymorphone which relieve intestinal immobility

Compound shall mean N-methylnaltrexone having the chemical structure C21H26BrNO.

Field of Use
MNTX is a selective, peripheral, opioid-receptor antagonist that reverses certain side effects induced by opioid use. MNTX competes with opioid analgesics for binding sites on opioid receptors, but is unable to cross the blood-brain barrier. As a result, MNTX “turns off” the effects of opioid analgesics outside the central nervous system, including the gastrointestinal tract, but does not interfere with opioid activity within the central nervous system. Therefore, MNTX does not block the pain relief that the opioids provide. To date, patients treated with MNTX in addition to opioid pain medications have experienced a reversal of many of the side effects induced by the opioids and have reported no decline in pain relief. MNTX has been studied in numerous clinical trials. To date, MNTX has been generally well tolerated and highly active in blocking opioid-related side effects without interfering with pain relief.

IPSCIO Record ID: 111868

License Grant
Licensor grants an exclusive, world-wide license to make, have made, use, sell or import Product pursuant to the Intellectual Property Rights or any other Licensor Technical Information. The term of the license shall be either the term of Phase A or, if Licensee elects to proceed with Phase B, the sum of the terms of Phase A and Phase B.

Phase A is for completing studies sufficient to establish the therapeutic index of the Compound and of whether Licensee intends to initiate Phase B.  Phase B is for developing and commercializing the Compound or Product.

License Property
Licensor has acquired from a third party, an exclusive, world-wide license to make, have made, use or sell (+)-[2(S)-[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-acetic acid and all pharmaceutically acceptable salts and solvates thereof (the Compound), with the right to sublicense.

ADL 8-2698 is a peripherally-acting, gastrointestinal tract-restricted mu opioid receptor antagonist.  ADL 8-2698 is for treatment of narcotic bowel dysfunction.
Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics.  As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation.

Field of Use
Licensee is engaged in the development and marketing of therapeutic products utilizing opiate receptor-mediated pathways.

Licensee are developing orally-administered ADL 8-2698 to block the adverse gastrointestinal side effects of narcotics without blocking the beneficial analgesic effects. These gastrointestinal side effects include narcotic bowel dysfunction, ileus, which is delayed recovery of bowel function after surgery, and nausea.

IPSCIO Record ID: 266852

License Grant
The German Licensor grants an exclusive, except with regard to Licensor, world-wide right and license under the Licensor Patents and Licensor Know-How and Licensors rights in the Joint Patents, Joint Know-How and Joint Research Technology, to conduct the Research.

Licensor grants the exclusive right to use and to disclose to Third Parties all regulatory and clinical documentation and data developed by or on behalf of Licensor in the Territory in connection with this Agreement and required to be disclosed to Licensee under this Agreement, as reasonably necessary or desirable in connection with the development and commercialization of pharmaceutical products in the Field in the Rest of World or outside the Field throughout the world.

Licensor agrees to negotiate in good faith with Licensee concerning the terms of a license under the Licensor Patents and the Licensor Know-How covering the composition of matter or the use of the Terminated Compounds, to permit Licensee to research, develop, make, have made, import, use, sell and offer for sale the Terminated Compounds outside the Field throughout the world.

Licensor grants an exclusive, including with regard to Licensor, right and license in the Rest of World under the Licensor Patents and the Licensor Know-How and under Licensors rights in the Joint Patents, Joint KnowHow and Joint Research Technology, to research and develop, and to make, have made, import, use, sell and offer for sale pharmaceutical products, including Licensed Products, in the Field.

License Property
Licensor is engaged in the research, development and marketing of products for the treatment of, among other things, ulcerative colitis.

Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound.  Development Compound means any Collaboration Compound that has
been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.

The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.

Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.

Field of Use
Field means the treatment or prevention in humans of one or more Indications.   Indication means ulcerative colitis; and other gastrointestinal and liver diseases.

Licensee possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.

IPSCIO Record ID: 26279

License Grant
The Licensor entered into a collaboration Agreement with the Licensee for the exclusive worldwide development and commercialization of Entereg for certain indications. The Licensor is responsible for the development of acute indications, such as postoperative ileus, and the Licensee is responsible for the development of chronic indications, such as opioid bowel dysfunction. In the United States, the Licensee and the Licensor are co-developing Entereg and intend to share profits or losses that result from the sale of the product.
License Property
Entereg is a drug which behaves as a peripherally acting µ-opioid antagonist. With limited ability to cross the blood–brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawal.

Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.

IPSCIO Record ID: 271161

License Grant
For the Research and Development License, Licensor grants to the German Licensee during the R&D Term a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology and under Licensors rights in the Joint Patents, Joint Research Technology and Joint Know-How, solely to conduct the Research, to characterize, optimize, research and develop the Development Compounds into Licensed Products in the Field and to make, have made and use Collaboration Compounds in the Field solely for research and development purposes in accordance with the Research and Development Plan and each Semi-Annual R&D Plan.

For the Commercialization License, Licensor grants to Licensee and its Affiliates a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to make, have made, import and use Licensed Products for use in the Field; and an exclusive, including with regard to Licensor right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to sell and offer for sale Licensed Products for use in the Field.

License Property
Licensor possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.

Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound.  Development Compound means any Collaboration Compound that has been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.

The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.

Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.

Field of Use
Field means the treatment or prevention in humans of one or more Indications.   Indication means ulcerative colitis; and other gastrointestinal and liver diseases.

Ulcerative colitis is a long-term condition that results in inflammation and ulcers of the colon and rectum.

IPSCIO Record ID: 260459

License Grant
Licensor grants to the Licensee of Sweden an exclusive license, with the right to grant sublicenses, under the Licensed Technology to make, use, have made, sell, offer for sale, import, and export Products in the Field of Use in the Territory.

Licensor grants a license to use the Licensor House Marks in connection with the Commercialization of Licensor Products in the Field of Use in the Territory.

Licensor grants an option for a period of twenty-four months the Japan Option Period after the Effective Date to include Japan in the Territory to Licensee.

License Property
Licensors Product means any product that combines a Gastroprotective Agent and any NSAID in a single fixed combination dosage form, that would, if made, used, sold, offered for sale, had made, imported or exported without a license from Licensor of the Licensed Patents, infringe one or more Valid Claims of the Licensed Patents.

Esomeprazole means that certain pharmaceutical compound with the name (5-methoxy-2-{(S)-[ ( 4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl }-1 H-benzimidazole ), including any salts, hydrates, solvates, polymorphs and tautomers thereof.

Naproxen means that certain pharmaceutical compound with the chemical name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneaceti,c acid, including any esters, salts, hydrates, solvates and polymorphs thereof.

The patent is for Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs.

Field of Use
Field of Use means the treatment of human diseases and conditions by means of a pharmaceutical product.  These Pharmaceutical Compositions are for the Coordinated Delivery of NSAIDs.

IP relates to the sublicenses’s proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet.  Naproxen is used to relieve pain from various conditions such as headache, muscle aches, tendonitis, dental pain, and menstrual cramps. It also reduces pain, swelling, and joint stiffness caused by arthritis, bursitis, and gout attacks. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).

IPSCIO Record ID: 3196

License Grant
Licensor hereby grant to Licensee, and Licensee hereby accepts in respect of the Licensed Technology and the Licensors’ interest in the Joint Technology:  (a) the exclusive license, even as to the Licensor and their Affiliates, with the right to grant Sublicenses (i) to Develop the Compound and Products in the Territory for use and Commercialization in the Field in the Territory and (ii) to Commercialize Products in the Field in the Territory; and (b) a non-exclusive license, with the right to grant Sublicenses to Manufacture or have Manufactured in the Territory (i) Products for use or Commercialization by Licensee and its Sublicensees under the license granted and (ii) Compound for incorporation into such Products.

The Licensor granted License of relevant know-how, patent rights and technology,for Relistor® (methylnaltrexone bromide) subcutaneous injection, to the Licensee, a leading gastrointestinal disease specialty company.

License Property
Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class therapy for opioid-induced constipation (OIC).

OIC is the constipation that often arises when patients take opioids for pain relief.

IPSCIO Record ID: 87659

License Grant
The license to be granted by Licensor to Licensee is a royalty-bearing license under all applicable patent and other proprietary rights of Licensee, including without limitation rights under the Technology and Licensee’s interest in the New Inventions and Joint Inventions to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) the Products in the Field in the Territory.

Subject to the Right of First Refusal and Option below, Licensor shall not license to any third party, and hereby grants an exclusive option to Licensee to license, the Licensor IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone for treatment or prevention of opioid overdose in the Territory.

License Property
Product: Pharmaceutical formulations containing the Compound as an active ingredient and the Excipient.

Compound: Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.

Option Compound: Naltrexone and nalmephene/ nalmefene.

Naloxone is a medication used to block the effects of opioids, especially in overdose.[1] Naloxone may be combined within the same pill as an opioid to decrease the risk of misuse.

Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness. An opioid is sometimes called a narcotic.

Field of Use
This agreement pertains to the treatment or prevention of any disease, disorder, state, condition or malady in humans except in the Opioid Field, provided that upon election of Opiant in writing and payment of the Option Fee, the “Field” shall include the Opioid Field.

Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.

Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.

IPSCIO Record ID: 280326

License Grant
The parties wish to enter into a collaboration employing Licensees medicinal chemistry, analytical chemistry and primary biology capabilities and Licensors chemistry, in vitro biology, and in vivo biology capabilities, in order to develop and commercialize pharmaceutical compounds subject to and in accordance with the terms and conditions of this Agreement (the “Collaboration”).

License to Commercialize Collaboration Compounds – With respect to all Collaboration Compounds for which Licensee has received Licensors approval to develop and commercialize, Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensor’s interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds –  Licensor grants to Licensee a worldwide, perpetual, exclusive, royalty-free license, with the right to sublicense, under Licensors interest in the Collaboration IP, to exploit for any and all purposes all compounds (other than Collaboration Compounds) derived, directly or indirectly, from Licensee Compounds.

Research Licenses – The Parties hereby grant each other non-exclusive, worldwide, royalty-free research licenses, without the right to sublicense, under their respective interests in the Licensee IP, Licensor IP and Collaboration IP, in order for each Party to perform its research obligations pursuant to Research Plans during the Collaboration Term.

License Property
Collaboration Product shall mean a pharmaceutical product containing a Collaboration Compound that is sold by Licensor or Licensee, or their respective Sublicensees or Affiliates.  It is understood that, in the event any Collaboration Compound is sold for therapeutic purposes, such Collaboration Compound shall be deemed a Collaboration Product and shall be subject to milestones and royalties as set forth in this Agreement.

Collaboration Compound shall mean a Licensee Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensor Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC.  A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensee or Licensor or their Affiliates to protect any compound in category (i), (ii) or (iii) above.  A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above.  For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensor Compound, Licensee Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound.

Joint Research Committee or “JRC” shall mean the entity organized to manage the scientific implementation of the Collaboration.

Licensor IP shall mean Licensor Patents and Licensor Know-how.

Collaboration IP shall mean Collaboration Patents and Collaboration Know-how.  Collaboration IP shall not include Licensee IP or Licensor IP.

Licensee IP shall mean Licensee Patents and Licensee Know-how.  Licensee IP shall not include any intellectual property owned or licensed by Licensee or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).

Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the effective date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the Effective Date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensor, Licensee or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensee or Licensor during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensor Patents or Licensee Patents.

Licensee Compound shall mean any compound brought to the Collaboration by Licensee, which is Controlled by Licensee at or after the Effective Date, and which is proprietary to Licensee by virtue of being within the Licensee IP.

Field of Use
Licensee Field shall mean, with respect to each Collaboration Compound for which Licensee has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

Licensor Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.

IPSCIO Record ID: 203524

License Grant
Licensor grants an exclusive, except as to Licensor for internal research purposes only and not for clinical development, license under Know How, the Licensed Patents arid the Process Licensed Patents, to develop, obtain Regulatory Approval for, use, make, have made, import, sell, and offer for sale New Compounds and New Products in the Territory.
License Property
The patents, related foreign equivalents and know-how relate to peripherally selective opioid antagonists.

The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.

The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.

Field of Use
The Field of Use means all uses as a Peripherally Selective Opioid Receptor Antagonist, where the term Peripherally Selective Opioid Receptor Antagonist shall mean a chemical entity that has a selectivity ratio of greater than 20 upon parenteral administration as measured by the ED-50 for antagonism of analgesia in the mouse writhing test in morphine-naive mice divided by the ED-50 for precipitation of diarrhea in the morphine-dependent mice test.

Licensee is developing  alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications.  Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.

IPSCIO Record ID: 233475

License Grant
For the Exclusive License Grant, the Licensor of Scotland, operating in the United Kingdom, grants  an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound and Product in the Territory. The exclusive license granted includes the right to grant sublicenses.

And, for the Exclusive License Grant, Licensor grants an exclusive license to use and exploit the NOS Patent Assets and the Licensors NOS Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of the NOS Inhibitor Technology and any NOS Inhibitor and the Split Dose Patent Assets and the Licensors Split Dose Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound or Product using the Split Dose Technology, each solely in connection with the use of Compound and/or Product in the Territory.  The exclusive license granted includes the right to grant sublicenses.

License Property
The rights are to a series of novel vascular targeting agents for cancer treatment from Licensor.  The targeting agents are known as the ANG-600 series.

The Product shall mean any product in final form for commercial sale by prescription, over-the-counter, or by any other method, or, where the context so indicates, the product being tested in clinical trials, which contains Compound as at least one of the therapeutically active ingredients, in all final dosage forms and package configurations for any indication, or any line extension thereof.

The Compound shall mean the chemical compounds known as benzimidazole carbamate class vascular targeting agents,including those designated ANG-600 Series, whose more specific chemical names are 5 (6) substituted benzimidazole-2-carbamates, and any derivative, homolog, analog or conjugate of any of the foregoing, and any isomer, salt, hydrate, solvate, metabolite, or prodrug or the like of any of the foregoing.

The NOS Inhibitor shall mean a chemical composition that inhibits the formation or action of nitric oxide, including those disclosed in the NOS Patent Assets.

NOS Inhibitor Technology shall mean technology relating to the combination of vascular targeting agents, including Compound, and an NOS Inhibitor, including the inventions disclosed in the NOS Patent Assets.

NOS Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement:
– are owned by Llicensor (including Licensors interest in jointly owned patents and patent applications) or which Licensor through license or otherwise has or acquires rights, and
– relate to the combination with Compound or Product of an NOS Inhibitor or the NOS Inhibitor Technology including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor NOS Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.

Split Dose Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement:
– are owned by Licensor including Licensors interest in jointly owned patents and patent applications or which Licensor through license or otherwise has or acquires rights, and
– relate to the use of Compound or Product in divided doses including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor Split Dose Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.

The Split-Dose Technology shall mean a method of administering any vascular damaging agent in a divided dose, including the inventions disclosed in the Split-Dose Patent Assets.

Field of Use
The application of the product is novel vascular targeting agents for cancer treatment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.